Laura Fanning
Overview
Explore the profile of Laura Fanning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lovett A, Chary S, Babu S, Bruneteau G, Glass J, Karlsborg M, et al.
Muscle Nerve
. 2025 Feb;
PMID: 40017137
Introduction/aims: Tofersen is approved for the treatment of amyotrophic lateral sclerosis (ALS) due to superoxide dismutase 1 mutations (SOD1-ALS). Here we report serious neurologic adverse events (AEs) that occurred in...
2.
Mongkhon P, Singkham N, Ponok K, Liamsrijan N, Phoosa W, Phattanasobhon S, et al.
Drug Saf
. 2024 Aug;
48(1):25-42.
PMID: 39214955
Introduction: Off-label underdosed direct oral anticoagulants (DOACs) are commonly utilised in Asian patients with atrial fibrillation (AF) since they are prone to bleeding with OACs. However, the efficacy and safety...
3.
Irving A, Petrie D, Harris A, Fanning L, Wood E, Moore E, et al.
PLoS One
. 2024 Aug;
19(8):e0308812.
PMID: 39190684
Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem...
4.
Carrillo de Albornoz S, Higgins A, Petrie D, Irving A, Fanning L, Weinkove R, et al.
Blood Adv
. 2024 Mar;
8(9):2259-2267.
PMID: 38484199
Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its...
5.
Spinks J, Violette R, Boyle D, Petrie D, Fanning L, Hall K, et al.
Med J Aust
. 2023 Aug;
219(7):325-331.
PMID: 37586750
Background: Medicines are the most frequent health care intervention type; their safe use provides significant benefits, but inappropriate use can cause harm. Systemic primary care approaches can manage serious medication-related...
6.
Kupelian V, Viscidi E, Hall S, Li L, Eaton S, Dilley A, et al.
Neurol Clin Pract
. 2023 Mar;
13(1):e200110.
PMID: 36891280
Background And Objectives: Reduced mobility in patients with amyotrophic lateral sclerosis (ALS) is hypothesized to increase the risk of venous thromboembolism (VTE). A few small, single-center studies have investigated the...
7.
Benatar M, Wuu J, Andersen P, Bucelli R, Andrews J, Otto M, et al.
Neurotherapeutics
. 2022 Sep;
19(5):1686.
PMID: 36175782
No abstract available.
8.
Miller T, Cudkowicz M, Genge A, Shaw P, Sobue G, Bucelli R, et al.
N Engl J Med
. 2022 Sep;
387(12):1099-1110.
PMID: 36129998
Background: The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations...
9.
Benatar M, Wuu J, Andersen P, Bucelli R, Andrews J, Otto M, et al.
Neurotherapeutics
. 2022 May;
19(4):1248-1258.
PMID: 35585374
Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream...
10.
Fanning L, Woods E, Hornung C, Perrett K, Tang M, Dalziel K
Value Health
. 2022 Mar;
25(8):1460-1462.
PMID: 35292193
No abstract available.